Professor, Bioengineering, Stanford University Medical Center
Internal Medicine
Dr. Russ B. Altman, MD
|
|
Give Review
Russ Altman practices Internal Medicine. He studied medicine at Stanford University School of Medicine. Stanford University School of Medicine is one of the top medical schools in the US. Stanford University School of Medicine is ranked 2/25 in Research/PrimaryCare. He over the years received 2 awards: "Elected Member" and "Fellow". Doctor Russ B. Altman, MD is a published doctor. He has 100 publications published. The most current publication "PharmGKB summary: very important pharmacogene information for RYR1."
Publications
- PharmGKB summary: very important pharmacogene information for RYR1.
- Informatics: Make sense of health data.
- Potential Adverse Effects of Anesthesia in Children-Reply.
- Assessment of the Radiation Effects of Cardiac CT Angiography Using Protein and Genetic Biomarkers.
- PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.
- Variations in the Binding Pocket of an Inhibitor of the Bacterial Division Protein FtsZ across Genotypes and Species.
- PharmGKB summary: ibuprofen pathways.
- Enabling the curation of your pharmacogenetic study.
- PharmGKB summary: very important pharmacogene information for CFTR.
- PharmGKB summary: very important pharmacogene information for CYP4F2.
- PharmGKB summary: gemcitabine pathway.
- PharmGKB summary: tramadol pathway.
- PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.
- PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.
- Reconstruction of the mouse otocyst and early neuroblast lineage at single-cell resolution.
- Knowledge-based fragment binding prediction.
- Guidelines for investigating causality of sequence variants in human disease.
- PharmGKB summary: very important pharmacogene information for UGT1A1.
- Environmental and state-level regulatory factors affect the incidence of autism and intellectual disability.
- PharmGKB summary: abacavir pathway.
- PharmGKB summary: very important pharmacogene information for SLC22A1.
- Clinical interpretation and implications of whole-genome sequencing.
- Integrating Systems Biology Sources Illuminates Drug Action.
- Coherent functional modules improve transcription factor target identification, cooperativity prediction, and disease association.
- PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics.
- Cloud-based simulations on Google Exacycle reveal ligand modulation of GPCR activation pathways.
- PharmGKB summary: mycophenolic acid pathway.
- PharmGKB summary: venlafaxine pathway.
- Using Molecular Features of Xenobiotics to Predict Hepatic Gene Expression Response.
- PharmGKB summary: methylene blue pathway.
- CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-analysis of Heterogeneous Study Populations.
- Identifying phenotypic signatures of neuropsychiatric disorders from electronic medical records.
- PharmGKB summary: tamoxifen pathway, pharmacokinetics.
- PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor.
- Challenges in the pharmacogenomic annotation of whole genomes.
- PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.
- PharmGKB summary: diuretics pathway, pharmacodynamics.
- PharmGKB summary: cyclosporine and tacrolimus pathways.
- Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.
- Response to 'Use of an algorithm for identifying hidden drug-drug interactions in adverse event reports' by Gooden et al.
- Web-scale pharmacovigilance: listening to signals from the crowd.
- Valproic acid pathway: pharmacokinetics and pharmacodynamics.
- Informatics confronts drug-drug interactions.
- Personal genomic measurements: the opportunity for information integration.
- Introduction to translational bioinformatics collection.
- Chapter 7: Pharmacogenomics.
- PharmGKB summary: zidovudine pathway.
- PharmGKB summary: very important pharmacogene information for GSTT1.
- PharmGKB summary: very important pharmacogene information for CYP3A5.
- Metformin pathways: pharmacokinetics and pharmacodynamics.
- PharmGKB summary: phenytoin pathway.
- Very important pharmacogene summary for VDR.
- PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6.
- Celecoxib pathways: pharmacokinetics and pharmacodynamics.
- Personal omics profiling reveals dynamic molecular and medical phenotypes.
- PharmGKB summary: very important pharmacogene information for G6PD.
- Using multiple microenvironments to find similar ligand-binding sites: application to kinase inhibitor binding.
- Simbios: an NIH national center for physics-based simulation of biological structures.
- PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19.
- PharmGKB summary: very important pharmacogene information for CYP1A2.
- Fast flexible modeling of RNA structure using internal coordinates.
- Phased whole-genome genetic risk in a family quartet using a major allele reference sequence.
- Cooperative transcription factor associations discovered using regulatory variation.
- A new disease-specific machine learning approach for the prediction of cancer-causing missense variants.
- PharmGKB summary: carbamazepine pathway.
- 2010 Translational bioinformatics year in review.
- RNA molecules with conserved catalytic cores but variable peripheries fold along unique energetically optimized pathways.
- CAMPAIGN: An open-source Library of GPU-accelerated Data Clustering Algorithms.
- A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports.
- PharmGKB summary: dopamine receptor D2.
- Bioinformatics Challenges for Personalized Medicine.
- PharmGKB summary: citalopram pharmacokinetics pathway.
- Databases in the area of pharmacogenetics.
- PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2.
- Remote thioredoxin recognition using evolutionary conservation and structural dynamics.
- PharmGKB summary: fluoropyrimidine pathways.
- Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).
- PharmGKB summary: methotrexate pathway.
- PharmGKB: very important pharmacogene--HMGCR.
- Bisphosphonates pathway.
- Independent component analysis: mining microarray data for fundamental human gene expression modules.
- KCNH2 pharmacogenomics summary.
- Using text to build semantic networks for pharmacogenomics.
- PharmGKB summary: very important pharmacogene information for PTGS2.
- Doxorubicin pathways: pharmacodynamics and adverse effects.
- SLC19A1 pharmacogenomics summary.
- Platelet aggregation pathway.
- VKORC1 pharmacogenomics summary.
- The utility of general purpose versus specialty clinical databases for research: warfarin dose estimation from extracted clinical variables.
- Turning limited experimental information into 3D models of RNA.
- Thiopurine pathway.
- PharmGKB summary: very important pharmacogene information for CYP2B6.
- Clopidogrel pathway.
- Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9.
- Very important pharmacogene summary: thiopurine S-methyltransferase.
- Vascular endothelial growth factor pathway.
- Cytochrome P450 2C9-CYP2C9.
- Using pre-existing microarray datasets to increase experimental power: application to insulin resistance.
- PharmGKB summary: very important pharmacogene information for angiotensin-converting enzyme.
Schools
Stanford Univ Sch Of Med
Stanford Hospital
Doctors Specialties
- Clinical Informatics
- Internal Medicine
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- Blue Cross Blue Shield of California PPO
- Access Plus Savenet
- Basic PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Awards
- Elected Member
- Fellow
Education
-
Stanford University -
Stanford University School of Medicine
Hospital
-
Stanford Health Care
Helpful Reviews
Similar Doctors
|
|
Dr. Pushpasree Sajja, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eliza G. Bennitt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Louanne M. Tourangeau, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jean K. Waltuch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott H. Wood, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher A. Longhurst, MD |
|
|
Dr. Rachel M. Seaman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sadick J. Alsadir, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Frank B. McDowell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tiffany Ly, MD |
|
|
Dr. David J. Pizzuti, MD |